Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMAT: IsaRD in Multiple Myeloma Patients With Persistent Marrow MRD Post-Transplant
NCT05690984Phase 2Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2023
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Medical College of Wisconsin. Started Jun 2023; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05690984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690984.